
In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219
INDICATIONS
Symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.
CONTRAINDICATIONS
OKi throat 0.16% spray for oral mucosa must not be administered in case of hypersensitivity to the active ingredient, to other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients, to patients in whom substances with a similar mechanism of action (for example acetylsalicylic acid or other NSAIDs) cause asthma attacks, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic edema, in case of previous bronchial asthma, during pregnancy and breastfeeding.
WARNINGS AND PRECAUTIONS FOR USE
The use, especially if prolonged, of topical drugs could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt suitable therapeutic measures. This medicine contains methyl parahydroxybenzoate, known to cause allergic reactions (including delayed reactions). This medicine contains mint flavouring, which in turn contains d-limonene, eugenol and linalool which may cause allergic reactions. This medicine contains the ever cool flavour, which itself contains linalool which may cause allergic reactions.
INTERACTIONS
At present there are no known interactions with other drugs: interactions which can also be excluded by considering the route of administration and the dosage of drug administered.
SIDE EFFECTS
Local side effects following topical administration on the oral mucosa of ketoprofen lysine salt solution are extremely rare and consist of irritative or allergic phenomena (angioneurotic edema), especially in subjects with hypersensitivity to NSAIDs. However, no systemic side effects emerged considering the route of administration and the dosage of drug administered. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse








